<HTML>


<HEAD>








<TITLE> </TITLE>


<META NAME="subject" CONTENT=" ">


<META NAME="keywords" CONTENT=" ">


<META NAME="doccomm" CONTENT=" ">


<META NAME="SWDocID" CONTENT="US1DOCS 5049275v1">


</HEAD>


<BODY LINK="#0000ff">





<P ALIGN="CENTER"><A NAME="_DV_M0"></A>UNITED STATES<BR>


SECURITIES AND EXCHANGE COMMISSION<BR>


WASHINGTON, D.C. 20549</P>


<P ALIGN="CENTER"><CENTER><TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=192>


<TR><TD VALIGN="TOP">&nbsp;</TD>


</TR>


</TABLE>


</CENTER></P>





<P ALIGN="CENTER"><A NAME="_DV_M1"></A>FORM 8-K</P>


<P ALIGN="CENTER"><A NAME="_DV_M2"></A>CURRENT REPORT<BR>


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</P>


<P ALIGN="CENTER"><A NAME="_DV_M3"></A>Date of Report (Date of earliest event reported):  April 6, 2005 (March 31, 2005)</P>


<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=638>


<TR><TD VALIGN="TOP">


<P ALIGN="CENTER">BOSTON LIFE SCIENCES, INC.</TD>


</TR>


</TABLE>





<P ALIGN="CENTER"><A NAME="_DV_M4"></A>(Exact Name of Registrant as Specified in Charter)</P>


<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=638>


<TR><TD WIDTH="33%" VALIGN="TOP">


<P ALIGN="CENTER">Delaware</TD>


<TD WIDTH="33%" VALIGN="TOP">


<P ALIGN="CENTER">0-6533</TD>


<TD WIDTH="33%" VALIGN="TOP">


<P ALIGN="CENTER">87-0277826</TD>


</TR>


<TR><TD WIDTH="33%" VALIGN="TOP">


<P ALIGN="CENTER">(State or Other Juris-<BR>


diction of Incorporation</TD>


<TD WIDTH="33%" VALIGN="TOP">


<P ALIGN="CENTER">(Commission<BR>


File Number)</TD>


<TD WIDTH="33%" VALIGN="TOP">


<P ALIGN="CENTER">(IRS Employer<BR>


Identification No.)</TD>


</TR>


</TABLE>





<P ALIGN="CENTER"></P>


<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=638>


<TR><TD WIDTH="56%" VALIGN="TOP">


<P ALIGN="CENTER">20 Newbury Street, 5<SUP>th</SUP> Floor, Boston, Massachusetts</TD>


<TD WIDTH="44%" VALIGN="TOP">


<P ALIGN="CENTER">02116</TD>


</TR>


<TR><TD WIDTH="56%" VALIGN="TOP">


<P ALIGN="CENTER">(Address of Principal Executive Offices)</TD>


<TD WIDTH="44%" VALIGN="TOP">


<P ALIGN="CENTER">(Zip Code)</TD>


</TR>


</TABLE>





<P ALIGN="CENTER"></P>


<P ALIGN="CENTER"><A NAME="_DV_M5"></A>Registrant's telephone number, including area code:  (617) 425-0200</P>


<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=638>


<TR><TD VALIGN="TOP">&nbsp;</TD>


</TR>


<TR><TD VALIGN="TOP">


<P ALIGN="CENTER">(Former Name or Former Address, if Changed Since Last Report)</TD>


</TR>


</TABLE>





<P ALIGN="CENTER"></P>


<P><A NAME="_DV_M6"></A>&#9;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below):</P>


<P><A NAME="_DV_M7"></A>&#9;<FONT FACE="Wingdings">&#168;</FONT>


<A NAME="_DV_M8"></A>&#9;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>


<P><A NAME="_DV_M9"></A>&#9;<FONT FACE="Wingdings">&#168;</FONT>


<A NAME="_DV_M10"></A>&#9;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>


<P><A NAME="_DV_M11"></A>&#9;<FONT FACE="Wingdings">&#168;</FONT>


<A NAME="_DV_M12"></A>&#9;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>


<P><A NAME="_DV_M13"></A>&#9;<FONT FACE="Wingdings">&#168;</FONT>


<A NAME="_DV_M14"></A>&#9;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>


<B><P><A NAME="_DV_M15"><A NAME="_DV_M24"></A></A>Item 8.01.  Other Events.</P>


</B>


<P><A NAME="_DV_M25"></A>On April 6, 2005, Boston Life Sciences, Inc., a Delaware corporation (the &quot;Company&quot;) announced that the report of the Company's independent registered public accounting firm regarding the Company's 2004 financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2004 contained an explanatory paragraph regarding the Company's ability to continue as a going concern. </P>





<P>The foregoing statement are qualified in its entirety by the Company's press release, a copy of which is filed herewith as Exhibit 99.1 and incorporated herein by reference.</P>


<B><P>Item 9.01. Financial Statements and Exhibits. <BR>


</P>


<P>&#9;</B>(c)&#9;Exhibits</P>


<P>&#9;&#9;See Exhibit Index attached hereto.</P>


<B>


</B><P ALIGN="CENTER"><A NAME="_DV_M36"></A>SIGNATURE</P>


<P><A NAME="_DV_M37"></A>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>





<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>


<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>


<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>


<P>Boston Life Sciences, Inc.</TD>


</TR>


<TR><TD WIDTH="50%" VALIGN="TOP">


<P>Date:  April 6, 2005</TD>


<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>


<P>By:  <U>/s/ Jospeh Hernon</U></TD>


</TR>


<TR><TD WIDTH="56%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>


<TD WIDTH="44%" VALIGN="TOP">


<P>Joseph Hernon</P>


<P>Chief Financial Officer and Secretary</TD>


</TR>


</TABLE>








<P> </P>


<P ALIGN="CENTER">&nbsp;</P>


<B><P ALIGN="CENTER">EXHIBIT INDEX </P></B>


<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=626>


<TR><TD WIDTH="13%" VALIGN="TOP">


<B><P ALIGN="CENTER">&nbsp;</B></TD>


<TD WIDTH="7%" VALIGN="TOP">&nbsp;</TD>


<TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>


</TR>


<TR><TD WIDTH="13%" VALIGN="TOP">


<B><U><P>Exhibit&nbsp;No.</P>


</B></U></TD>


<TD WIDTH="7%" VALIGN="TOP">


<B><U><P>&nbsp;&nbsp;</B></U></TD>


<TD WIDTH="80%" VALIGN="TOP">


<B><U><P>Description</P>


</B></U></TD>


</TR>


<TR><TD WIDTH="13%" VALIGN="TOP">


<P>99.1</TD>


<TD WIDTH="7%" VALIGN="TOP">


<P>&nbsp;&nbsp;</TD>


<TD WIDTH="80%" VALIGN="TOP">


<P>Press Release issued by Boston Life Sciences, Inc. on April 6, 2005.</TD>


</TR>


</TABLE>


</CENTER></P>





<P> </P>


<B></B></BODY>


</HTML>
[{"type": "8-K", "sequence": "1", "filename": "rrd75121.htm", "description": "FORM 8-K", "secsgml_size_bytes": 6101}]
{"company-data": {"conformed-name": "BOSTON LIFE SCIENCES INC /DE", "cik": "0000094784", "assigned-sic": "2834", "irs-number": "870277826", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-06533", "film-number": "05737724"}, "business-address": {"street1": "20 NEWBURY STREET", "street2": "5TH FLOOR", "city": "BOSTON", "state": "MA", "zip": "02116", "phone": "6174250200"}, "mail-address": {"street1": "20 NEWBURY STREET", "street2": "5TH FLOOR", "city": "BOSTON", "state": "MA", "zip": "02116"}, "former-company": [{"former-conformed-name": "GREENWICH PHARMACEUTICALS INC", "date-changed": "19920703"}, {"former-conformed-name": "STRATEGIC MEDICAL RESEARCH CORP /DE", "date-changed": "19790521"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  April 6, 2005 (March 31, 2005)
BOSTON LIFE SCIENCES, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
0-6533
87-0277826
(State or Other Juris-
diction of Incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
20 Newbury Street, 5
th
Floor, Boston, Massachusetts
02116
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:  (617) 425-0200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.  Other Events.
On April 6, 2005, Boston Life Sciences, Inc., a Delaware corporation (the "Company") announced that the report of the Company's independent registered public accounting firm regarding the Company's 2004 financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2004 contained an explanatory paragraph regarding the Company's ability to continue as a going concern.
The foregoing statement are qualified in its entirety by the Company's press release, a copy of which is filed herewith as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c)	Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Boston Life Sciences, Inc.
Date:  April 6, 2005
By:
/s/ Jospeh Hernon
Joseph Hernon
Chief Financial Officer and Secretary
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release issued by Boston Life Sciences, Inc. on April 6, 2005.